Background Preconception-initiated low-dose aspirin might positively aff ect pregnancy outcomes, but this possibility has not been adequately assessed. Our aim was to investigate whether low-dose aspirin improved livebirth rates in women with one to two previous pregnancy losses.
Introduction
Pregnancy loss is a common adverse event, estimated to occur in up to 30% of conceptions. 1 Women who have had a pregnancy loss are at increased risk of having a subsequent loss and other adverse pregnancy events. 2 The pathophysiological mechanisms that lead to adverse pregnancy outcomes are not fully understood, although decreased blood fl ow and increased infl ammation can have important roles. 3 Since aspirin can improve blood fl ow and reduce infl ammation in reproductive organs, 4 it might be useful for the improvement of pregnancy outcomes.
Post-conception use of low-dose aspirin has been studied extensively with respect to recurrent pregnancy loss (usually defi ned as at least two losses) and is often prescribed to prevent pregnancy loss, despite its unproven effi cacy. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Preconception use of low-dose aspirin improves endometrial growth and vascularisation in women undergoing in-vitro fertilisation (IVF). 15 Thus, preconception-initiated lowdose aspirin might positively aff ect downstream pregnancy outcomes during a crucial treatment window. However, this possibility has not been extensively assessed.
The aim of the Eff ects of Aspirin in Gestation and Reproduction (EAGeR) trial was to assess whether daily preconception-initiated treatment with low-dose aspirin improves the livebirth rate compared with placebo in women with one to two previous pregnancy losses.
Methods

Study design and participants
EAGeR was a multicentre, block-randomised, doubleblind, placebo-controlled clinical trial in four university medical centres in the USA. Inclusion and exclusion criteria have been detailed elsewhere. 16 Briefl y, initial inclusion criteria (applied for recruitment of the original stratum) included women aged 18-40 years who were actively trying to conceive and who had a history of only one previous pregnancy loss at less than 20 weeks' gestation during the previous year; up to one previous livebirth; up to one elective termination or ectopic pregnancy; regular menstrual cycles of 21-42 days in length during the preceding 12 months; and no history of infertility. These criteria were chosen because women with a recent pregnancy loss might have a healing endometrium and thereby benefi t from the positive eff ect of low-dose aspirin on blood fl ow, and because this population would be especially motivated to participate in the trial. Participants were recruited from the community as well as from the four clinical study centres.
Because of slow recruitment, the study was expanded to include four sites (rather than two as originally planned) and the inclusion criteria were extended to women who had one or two pregnancy losses, including at more than 20 weeks' gestation; pregnancy losses that occurred more than 1 year before enrolment; and up to two previous livebirths. These criteria were applied for recruitment of the expanded stratum. All other criteria were identical between the two eligibility strata. 16 To allow the assessment of outcomes specifi cally for the stratum recruited under the original eligibility criteria, participants were independently randomised within each eligibility stratum (original and expanded). Participants were questioned about the details of previous losses, and these losses were verifi ed with serum human chorionic gonadotropin (hCG) results, ultrasound fi ndings, physician investigation, medical records, and histology fi ndings. Participants were excluded if they had a major medical problem, a known contraindication to aspirin, or an indication for anticoagulant treatment.
The institutional review board at each participating centre approved the study, and participants provided written informed consent. A data safety and monitoring board provided oversight.
Randomisation and masking
Participants were randomly assigned in a 1:1 ratio to low-dose aspirin or placebo by study coordinators at each centre according to a computerised randomisation algorithm. The algorithm was developed by the study data coordinating centre and based on a permutedblock design, with block lengths of six or eight within each eligibility stratum (original and expanded) and centre. Participants, trial staff , and investigators were masked to the assigned treatment throughout the trial.
Procedures
Women received daily low-dose aspirin (81 mg [standard low dose in the USA]) plus 400 μg folic acid or placebo plus 400 μg folic acid. Study tablets (aspirin and placebo) were manufactured to be identical in appearance and weight, with folic acid given separately as a supplement. Study tablets were taken daily until completion of six menstrual cycles while attempting pregnancy, or until 36 weeks' gestation for those who became pregnant (up to roughly 60 weeks).
Study visits took place every 2 weeks for the fi rst 2 months, and were monthly thereafter. Adherence was self-reported daily and assessed by weighing of drug bottles at each study visit. Participants provided urine and blood samples and completed questionnaires at each study visit. Baseline questionnaires elicited demographic data and information about reproductive history and health behaviours, and follow-up questionnaires assessed safety and pregnancy events during the trial. All adverse events were reported directly to study staff by participants or through the questionnaires, which were reviewed by the adverse events committee. When indicated, participant medical records for the reported event were reviewed by the adverse events committee, which was masked to the assigned treatment. Participants in both treatment groups used fertility monitors (Clearblue Easy Fertility Monitor, Inverness Medical Innovations, Waltham, MA, USA) after receiving standard training to assist with the timing of intercourse. The study protocol has been reported previously. 16 Pregnancy was initially verifi ed by a clinic urine pregnancy test and then confi rmed by ultrasound at 6-7 weeks' gestation. If evidence of pregnancy was not apparent on ultrasound after a positive pregnancy test, the case was classifi ed as a periconception loss and the participant continued on the non-pregnancy follow-up schedule. Participation in the study ended when a woman either completed six menstrual cycles in the trial without becoming pregnant, or had two periconception losses. Participants who became pregnant were followed monthly until the pregnancy ended.
Outcome measures
The primary outcome was livebirth. Secondary outcomes were implantation (positive urine pregnancy test), confi rmed pregnancy (gestational sac on ultrasound, clinical recording of fetal heart tones, or a later-stage confi rmation of pregnancy), pregnancy loss (<20 weeks' gestation, after confi rmation of pregnancy), birthweight, and serious obstetric complications (pre-eclampsia, gestational diabetes, gestational hypertension, or preterm birth [<37 weeks' gestation]). These outcomes were obtained prospectively by maternal report and abstraction from medical records by trained staff . Gestational age was estimated from the early study ultrasound at 6-7 weeks' gestation. For participants with a pregnancy loss before the early ultrasound, gestational age was defi ned as the number of days between detection of ovulation by the fertility monitor and the date of the loss, plus 14 days.
Statistical analysis
The study was initially designed to detect a 10% absolute diff erence in livebirth rate with 80% power and a type I error rate of 5%, on the assumption that participants taking placebo who achieved pregnancy would have a livebirth rate of 75%. 16 Therefore, a sample size of 1254 was needed, on the basis of an assumed 40% pregnancy rate over 6 months of attempting. To account for a potential 20% loss to follow-up, the recruitment target was 1600 participants. Additional power calculations, done before the start of the study, incorporated the probability of conception over six cycles to obtain unconditional livebirth probabilities. These calculations confi rmed that 1600 recruited participants would provide power of more than 80% to detect a 10% increase in livebirths from low-dose aspirin. Analyses were based on the intention-to-treat principle (excluding participants lost to follow-up), with outcomes in the two groups compared by use of Fisher's exact and Student's t tests. SAS version 9.3 (SAS Institute, Cary, NC, USA) was used for all statistical analyses. Analyses were done for the entire population as well as stratifi ed by the two eligibility strata (original and expanded). An exploratory analysis was done to assess potential diff erences between treatment groups at diff erent stages of the reproductive process. A sensitivity analysis was used to assess the eff ect of early participant withdrawal from the trial on the outcome of livebirth. This trial is registered with ClinicalTrials.gov, number NCT00467363.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The data coordinating centre, led by NG and DF, had full access to the data throughout the trial, and did analyses as requested by the data safety monitoring board. On trial completion, the investigators employed by the funder (EFS, NJP, and SLM) and the data coordinating centre investigators (NG and DF) had full access to all study data. The corresponding author had the fi nal responsibility for the decision to submit for publication.
Results
1228 women were recruited and randomly assigned in blocks (by centre and eligibility stratum) between June 15, 2007, and July 15, 2011 . 1078 participants completed the study and were included in the analysis (fi gure 1). Treatment groups were similar with respect to the assessed demographic and baseline characteristics (table 1) .
Among all trial participants, the treatment groups did not diff er signifi cantly with respect to the primary outcome of livebirth rate, although a signifi cant diff erence was seen in the original stratum (table 2) . Table 3 shows the results for the secondary outcomes. More women receiving lowdose aspirin had positive urine hCG pregnancy tests than those taking placebo, both in the original stratum and in both strata combined. The number of ultrasoundconfi rmed pregnancies was also higher in the low-dose aspirin group than in the placebo group, for both the original stratum and both strata combined, although no signifi cant diff erence was seen in the expanded stratum alone. No signifi cant diff erences were seen between treatment groups in either stratum for pregnancy complications that occurred after implantation, including pregnancy loss ( treatment group in the original stratum were due to diff erences in pregnancy rates (whether based on a positive pregnancy test or confi rmed pregnancy) rather than any outcome conditional on pregnancy (ie, early pregnancy losses, stillbirths, etc; fi gure 2). Safety symptoms were assessed via questionnaire and results were similar for the two treatment groups (table 4). Staff -documented case report forms of serious adverse events were continuously monitored by a physicians' committee of investigators and by the data safety and monitoring board. No major birth defects were reported, and no diff erence was seen in the proportion of minor birth defects between the groups (four in each group). Of the four birth defects in the lowdose aspirin group, one was a cleft lip and three were ventricular septal defects, which is one of the most common fetal malformations in the general population. One case of transient pulmonary hypertension occurred in an infant in the low-dose asprin group. Three cases of neonatal death occurred; of the two deaths in the lowdose aspirin group, one was due to cervical insuffi ciency and the other was attributed to chronic vaginal bleeding, chorioamnionitis, and preterm birth. The committee also vetted the case report forms of minor adverse events, reporting that vaginal bleeding was more common in women who received low-dose aspirin (n=24 women) than in those given placebo (n=8 women; p=0·0038). However, the rate of pregnancy loss was not raised in women taking low-dose aspirin who experienced bleeding.
1212 women completed the adherence questionnaire after the fi rst menstrual cycle during follow-up, with 606 in each treatment group. Self-reported adherence to treatment assignment was similar between groups. 93 (15%) of women in the low-dose aspirin group permanently stopped taking the study drug, compared with 79 (13%) in the placebo group. Similarly, 34 (6%) women assigned to low-dose aspirin temporarily stopped taking the study drug, compared with 48 (8%) who stopped taking placebo. Weighing of drug bottles suggested similar rates of adherence (data not shown).
A sensitivity analysis done in the original stratum suggested that low-dose aspirin would have been associated with a signifi cant increase in livebirth rate for all reasonable assumptions about potential livebirth rates in the participa nts who withdrew early from each treatment group (data not shown).
Discussion
Overall, preconception-initiated treatment with low-dose aspirin was not signifi cantly associated with livebirth rates, pregnancy loss, or other pregnancy complications. To our knowledge, this is the fi rst study to show that preconception-initiated low-dose aspirin does not decrease the risk of pregnancy loss in women without a history of recurrent pregnancy loss (ie, only one to two previous losses). Thus, our data do not support the general use of low-dose aspirin to decrease the risk of pregnancy loss (panel).
Our results are consistent with fi ndings from several trials in women with recurrent losses (ie, two or more losses) who started aspirin treatment after conception, which showed no benefi t of low-dose aspirin for the prevention of pregnancy loss. 7 Low-dose aspirin combined with heparin confers some benefi t to a subset of women with recurrent pregnancy loss due to antiphospholipid syndrome. [20] [21] [22] [23] One small trial 6 (n=364 participants) assessed the reproductive eff ects of low-dose aspirin, low-dose aspirin plus heparin, or placebo on recurrent pregnancy loss, with 94 (26%) of the couples recruited before conception. 6 The results showed no benefi t from either treatment regimen compared with placebo. A possible explanation for these negative fi ndings could be the late initiation of low-dose aspirin treatment in pregnancy. Since placentation and organogenesis occur very early in pregnancy, postconception initiation of low-dose aspirin might miss the crucial window for positive intervention, emphasising the need for preconception trials.
A study population that has been consistently assessed before conception is patients undergoing IVF. Two metaanalyses 17, 18 showed that low-dose aspirin had no signifi cant eff ect on the clinical pregnancy rate (risk ratio 1·03, 95% CI 0·91-1·17) or livebirth rate (0·91, 0·72-1·15) in women undergoing IVF. Results of a systematic review 19 with less stringent quality criteria than these meta-analyses showed that although pregnancy rates were increased with low-dose aspirin (odds ratio 1·19, 1·01-1·39), livebirth rates were not aff ected (1·08, 0·82-1·68). Our study is the fi rst to show that low-dose aspirin does not decrease pregnancy loss when started before conception in women with a history of only one to two previous pregnancy losses. Low-dose aspirin alone has therefore not been shown to reduce pregnancy loss in any population.
In our trial, low-dose aspirin was associated with an increase in livebirth rate in women with a single, well documented pregnancy loss before 20 weeks' gestation during the previous year (ie, the original stratum). The eff ect could not be attributed to a lower pregnancy loss rate and was probably due to increased conception or implantation rates in women treated with low-dose aspirin. Furthermore, in the overall study population (ie, both strata combined), low-dose aspirin was associated 
Panel: Research in context
Systematic review
Aspirin has been used to treat various reproductive outcomes. Relevant to our work in this trial, we assessed the scientifi c literature with respect to the use of aspirin to prevent pregnancy loss in women with recurrent pregnancy loss (ie, more than two losses) both with and without antiphospholipid syndrome, and preconception treatment for women undergoing in-vitro fertilisation (IVF). Although a systematic review 9 reported in 2012 (including 13 studies and 849 participants) showed that combined unfractionated heparin and aspirin treatment reduced pregnancy loss by 54% in women with recurrent pregnancy loss associated with antiphospholipid antibodies, similar results were not seen in women without antiphospholipid syndrome. 7 Studies in women with a history of at least two miscarriages and without antiphospholipid syndrome were summarised in a systematic review 7 reported in 2009 (including two studies and 189 participants), which did not show a benefi t from aspirin treatment. Because only one of the two included studies was placebo-controlled, the reviewers called for large, randomised, placebo-controlled trials to be done. In IVF populations, a systematic review and meta-analysis 17 reported in 2011 (including 13 trials and 2653 participants) showed no signifi cant diff erences between livebirth rates, clinical pregnancy rates, or miscarriage rates in women treated with aspirin compared with placebo. Results from a meta-analysis of individual patient data (1119 participants) also showed no eff ects of aspirin on clinical or ongoing pregnancy rates. 18 However, a systematic review 19 with less stringent quality criteria (including 17 studies and 6403 participants) showed that aspirin increased pregnancy rates in IVF patients, although it had no eff ect on livebirth rates. We searched PubMed and the Cochrane Library for any additional original articles or systematic reviews reported since these previous reviews up to Sept 18, 2013 , using the terms "aspirin", "miscarriage", "pregnancy loss", and "pregnancy". We did not identify any relevant studies done in populations without a history of recurrent pregnancy loss (only one to two losses) and without antiphospholipid syndrome.
Interpretation
Preconception-initiated treatment with low-dose aspirin does not increase the rate of livebirth or reduce the rate of pregnancy loss in women with a history of one to two previous pregnancy losses. However, it might increase pregnancy rates in women with a single recent loss. Our results do not support the use of low-dose aspirin to decrease the risk of pregnancy loss. Further research should be done to investigate the potential eff ects of low-dose aspirin on fecundity and implantation.
with an increased rate of positive urine pregnancy tests. This eff ect was more pronounced in the original stratum, and not detectable in the expanded stratum alone. These data suggest that low-dose aspirin might have a favourable eff ect on fecundity or implantation for a subgroup of women, which is consistent with fi ndings from some IVF studies, which have shown eff ects on implantation, 15 but not livebirth rates. 19 The EAGeR trial diff ers from previous studies in several important ways. First, our study population did not have a history of recurrent pregnancy loss, but consisted of women with only one or two previous losses, most of which had occurred in the recent past. Women who have had several pregnancy losses probably have diff erent underlying pathological features from those with only one or two previous losses. Second, low-dose aspirin was started before conception, which could aff ect important early pregnancy events such as placentation, vascularisation, and organogenesis. Previously, preconception-initiated low-dose aspirin has only been assessed in a much smaller study 6 of non-IVF patients with recurrent pregnancy loss. Third, women in our study were block-randomised by eligibility stratum. This approach enabled assessment of the eff ect of low-dose aspirin on pregnancy outcomes in a more homogeneous group with very strict eligibility criteria (original stratum), as well as a more heterogeneous group, which more closely resembles the general population of women attempting pregnancy (expanded stratum).
Notably, the original stratum included the most reproductively healthy women, who were the least likely to be infertile or have a condition predisposing them to recurrent pregnancy loss. The fact that low-dose aspirin had a signifi cant eff ect on positive urine pregnancy tests for both strata combined lends support to the notion that low-dose aspirin could have favourable eff ects on fecundity in women with one to two previous losses. However, the fi nding of a signifi cant eff ect on our primary outcome in only one stratum, and the fact that a positive urine pregnancy test was a secondary outcome, should prompt caution. Our results should be regarded as hypothesis-generating and do not allow for defi nitive conclusions. They do not justify the use of low-dose aspirin to increase fecundity in similar women in the absence of further studies.
Importantly, our study showed that low-dose aspirin was not associated with an increase in major adverse events, either in pregnant women or in their fetuses and newborn babies. Indeed, randomised clinical trials [24] [25] [26] with thousands of participants have shown no increase in adverse fetal sequelae in maternal doses of up to 150 mg per day.
Our study had several limitations. First, too few cases were seen to defi nitively exclude the possibility of rare but serious adverse events. Second, the rigors of the study protocol were such that participants tended to have higher income and more education than average, so these results might not be applicable to women with lower socioeconomic status. Finally, 150 (12%) of 1228 women were lost to follow-up, which could be a potential source of bias. However, in view of the fact that loss to follow-up was similar between treatment groups, and based on the results of the sensitivity analysis, bias from loss to follow-up seems unlikely.
The strengths of the study included its rigorous design and high participant adherence to an extensive protocol. Trial outcomes were well defi ned and well documented. Participants were followed up with frequent scheduled study visits, the use of fertility monitors, and early ultrasound to precisely document pregnancy and pregnancy loss. Moreover, low-dose aspirin use was started before conception, setting this trial apart from most previous studies. Finally, the number of participants (even within the separate eligibility strata) was quite large compared with other studies.
In summary, daily low-dose aspirin started before conception was not associated with an increase in livebirths or a decrease in pregnancy loss in women with one to two previous losses. However, it was associated with an increased rate of positive urine pregnancy tests and a nearly 10% increase in livebirth rate in women with a single pregnancy loss at less than 20 weeks' gestation during the previous year. Because of the low cost, availability, and apparent safety of low-dose aspirin, these fi ndings should prompt further investigation into its eff ects on fecundity and implantation. However, our data do not support the general use of low-dose aspirin to decrease pregnancy loss or increase livebirth rates.
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